Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,579.20
(
-0.60%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
106.58
(
2.05%
)
Bitcoin
70,578.02
(
0.97%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 171040

Tuesday, 12/10/2013 4:09:43 PM

Tuesday, December 10, 2013 4:09:43 PM

Post# of 257262
ABBV/ENTA’s SAPHIRE-2 data (#msg-94817670) are so strong that, realistically, GILD can only hope to match them rather than exceed them.

No one I know expected a 96% SVR rate in this patient pool (treatment-experienced GT1a/GT1b of whom 49% were prior null responders) without any hint of a safety or tolerability problem.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up